Form 4 for GALT GALECTIN THERAPEUTICS INC
Accepted 2026-06-30 19:24:12 ET · period of report 2026-06-26 · accession 0001133416-26-000061 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| DMT | 2026-06-30 19:24 | 2026-06-26+ | GALT | Shlevin Harold H. | Dir | M - OptEx | $1.23 | +30.0K | 28.8K | New | +$36.9K |
| DMT | 2026-06-30 19:24 | 2026-06-26+ | GALT | Shlevin Harold H. | Dir | S - Sale+OE | $5.03 | -30.0K | 6,500 | -82% | -$150.9K |
| DMT | 2026-06-30 19:24 | 2026-06-26+ | GALT | Shlevin Harold H. | Dir | M - OptEx | $0.00 | -30.0K | 30.0K | -50% | $0 |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock | 2026-06-26 | M | A | 7,732 | $1.23 | 14,232 | D | — | — | (F1) The reported transaction was made pursuant to a Rule 10b5-1 plan adopted by the reporting person on August 29. 2025, as disclosed in the Issuers Quarterly Report on Form 10-Q, filed with the SEC on November 14, 2025 |
| 2 | Common | Common Stock | 2026-06-26 | S | D | 7,732 | $5.00 | 6,500 | D | — | — | (F1) The reported transaction was made pursuant to a Rule 10b5-1 plan adopted by the reporting person on August 29. 2025, as disclosed in the Issuers Quarterly Report on Form 10-Q, filed with the SEC on November 14, 2025 (F2) The shares were sold in multiple transactions at prices ranging from $5.00 to $5.01. This amount represents the weighted average sale price of such transactions. The reporting person undertakes to provide full information regarding the number of shares sold at each separate price upon request by the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer. |
| 3 | Common | Common Stock | 2026-06-29 | M | A | 22,268 | $1.23 | 28,768 | D | — | — | (F1) The reported transaction was made pursuant to a Rule 10b5-1 plan adopted by the reporting person on August 29. 2025, as disclosed in the Issuers Quarterly Report on Form 10-Q, filed with the SEC on November 14, 2025 |
| 4 | Common | Common Stock | 2026-06-29 | S | D | 22,268 | $5.04 | 6,500 | D | — | — | (F1) The reported transaction was made pursuant to a Rule 10b5-1 plan adopted by the reporting person on August 29. 2025, as disclosed in the Issuers Quarterly Report on Form 10-Q, filed with the SEC on November 14, 2025 (F4) The shares were sold in multiple transactions at prices ranging from $5.00 to $5.12. This amount represents the weighted average sale price of such transactions. The reporting person undertakes to provide full information regarding the number of shares sold at each separate price upon request by the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer. |
| 5 | Derivative | Stock Option (right to buy) | 2026-06-26 | M | D | 7,732 | $0.00 | 52,268 | D | $1.23 · 2025-12-31 to 2035-01-23 | 7,732 Common Stock | (F1) The reported transaction was made pursuant to a Rule 10b5-1 plan adopted by the reporting person on August 29. 2025, as disclosed in the Issuers Quarterly Report on Form 10-Q, filed with the SEC on November 14, 2025 (F3) The options vested 100% on December 31, 2025. |
| 6 | Derivative | Stock Option (right to buy) | 2026-06-29 | M | D | 22,268 | $0.00 | 30,000 | D | $1.23 · 2025-12-31 to 2035-01-23 | 22,268 Common Stock | (F1) The reported transaction was made pursuant to a Rule 10b5-1 plan adopted by the reporting person on August 29. 2025, as disclosed in the Issuers Quarterly Report on Form 10-Q, filed with the SEC on November 14, 2025 (F3) The options vested 100% on December 31, 2025. |